Shenzhen Kangzhe Pharmaceutical Co., Ltd. Report issue

For profit Phase 1 Phase 3
Founded: Shenzhen China (1985)
Status: No NME R&D (1985)

Organization Overview

First Clinical Trial
2011
NCT01489566
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

tildrakizumab (Ilumetri) (1 trial)

tyroserleutide (2 trials)

Drugs in Phase 1 Trials (1)

doxorubicin (Doxil) (1 trial)

Drugs in Other Trials (2)

aspergillus oryzae (1 trial)

pancreatin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 5